Literature DB >> 22011200

Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Natalie M Barkey1, Narges K Tafreshi, Jatinder S Josan, Channa R De Silva, Kevin N Sill, Victor J Hruby, Robert J Gillies, David L Morse, Josef Vagner.   

Abstract

The incidence of malignant melanoma is rising faster than that of any other cancer in the United States. Because of its high expression on the surface of melanomas, MC1R has been investigated as a target for selective imaging and therapeutic agents against melanoma. Eight ligands were screened against cell lines engineered to overexpress MC1R, MC4R, or MC5R. Of these, compound 1 (4-phenylbutyryl-His-dPhe-Arg-Trp-NH(2)) exhibited high (0.2 nM) binding affinity for MC1R and low (high nanomolar) affinities for MC4R and MC5R. Functionalization of the ligand at the C-terminus with an alkyne for use in Cu-catalyzed click chemistry was shown not to affect the binding affinity. Finally, formation of the targeted polymer, as well as the targeted micelle formulation, also resulted in constructs with low nanomolar binding affinity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22011200      PMCID: PMC3302579          DOI: 10.1021/jm201226w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

1.  Effects of macrocycle size and rigidity on melanocortin receptor-1 and -5 selectivity in cyclic lactam alpha-melanocyte-stimulating hormone analogs.

Authors:  Alexander V Mayorov; So-Yeop Han; Minying Cai; Matthew R Hammer; Dev Trivedi; Victor J Hruby
Journal:  Chem Biol Drug Des       Date:  2006-05       Impact factor: 2.817

2.  Cell signaling and trafficking of human melanocortin receptors in real time using two-photon fluorescence and confocal laser microscopy: differentiation of agonists and antagonists.

Authors:  Minying Cai; Eva V Varga; Magda Stankova; Alexander Mayorov; Joseph W Perry; Henry I Yamamura; Dev Trivedi; Victor J Hruby
Journal:  Chem Biol Drug Des       Date:  2006-10       Impact factor: 2.817

3.  Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.

Authors:  Lihui Wei; Clayton Butcher; Yubin Miao; Fabio Gallazzi; Thomas P Quinn; Michael J Welch; Jason S Lewis
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

4.  Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor.

Authors:  R Wang; R Kobayashi; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

5.  Novel 3D pharmacophore of alpha-MSH/gamma-MSH hybrids leads to selective human MC1R and MC3R analogues.

Authors:  Minying Cai; Alexander V Mayorov; Christopher Cabello; Magda Stankova; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

6.  Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells.

Authors:  W Siegrist; F Solca; S Stutz; L Giuffrè; S Carrel; J Girard; A N Eberle
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

7.  Molecular analysis of melanoma precursor lesions.

Authors:  Y Wang; U Rao; R Mascari; T J Richards; A J Panson; H D Edington; J M Shipe-Spotloe; S S Donnelly; J M Kirkwood; D Becker
Journal:  Cell Growth Differ       Date:  1996-12

8.  Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R).

Authors:  Heather L Handl; Rajesh Sankaranarayanan; Jatinder S Josan; Josef Vagner; Eugene A Mash; Robert J Gillies; Victor J Hruby
Journal:  Bioconjug Chem       Date:  2007-06-26       Impact factor: 4.774

9.  Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression.

Authors:  Z Wang; L Margulies; D J Hicklin; S Ferrone
Journal:  Tissue Antigens       Date:  1996-05

10.  4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.

Authors:  T K Sawyer; P J Sanfilippo; V J Hruby; M H Engel; C B Heward; J B Burnett; M E Hadley
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

View more
  24 in total

Review 1.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

Review 2.  The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases.

Authors:  Minying Cai; Victor J Hruby
Journal:  Curr Protein Pept Sci       Date:  2016       Impact factor: 3.272

3.  Discovery of Polypharmacological Melanocortin-3 and -4 Receptor Probes and Identification of a 100-Fold Selective nM MC3R Agonist versus a μM MC4R Partial Agonist.

Authors:  Katlyn A Fleming; Katie T Freeman; Mike D Powers; Radleigh G Santos; Ginamarie Debevec; Marc A Giulianotti; Richard A Houghten; Skye R Doering; Clemencia Pinilla; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2019-02-28       Impact factor: 7.446

4.  Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma.

Authors:  Narges K Tafreshi; Christopher J Tichacek; Darpan N Pandya; Michael L Doligalski; Mikalai M Budzevich; HyunJoo Kil; Nikunj B Bhatt; Nancy D Kock; Jane L Messina; Epifanio E Ruiz; Nella C Delva; Adam Weaver; William R Gibbons; David C Boulware; Nikhil I Khushalani; Ghassan El-Haddad; Pierre L Triozzi; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

Review 5.  Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.

Authors:  Shi Xu; Bogdan Z Olenyuk; Curtis T Okamoto; Sarah F Hamm-Alvarez
Journal:  Adv Drug Deliv Rev       Date:  2012-09-29       Impact factor: 15.470

6.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

7.  Development of a time-resolved fluorescence probe for evaluation of competitive binding to the cholecystokinin 2 receptor.

Authors:  N G R Dayan Elshan; Thanuja Jayasundera; Craig S Weber; Ronald M Lynch; Eugene A Mash
Journal:  Bioorg Med Chem       Date:  2015-02-26       Impact factor: 3.641

8.  In situ gelling silk-elastinlike protein polymer for transarterial chemoembolization.

Authors:  Azadeh Poursaid; Robert Price; Andrea Tiede; Erik Olson; Eugene Huo; Lawrence McGill; Hamidreza Ghandehari; Joseph Cappello
Journal:  Biomaterials       Date:  2015-04-28       Impact factor: 12.479

9.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

Review 10.  Malignant melanoma and melanocortin 1 receptor.

Authors:  A A Rosenkranz; T A Slastnikova; M O Durymanov; A S Sobolev
Journal:  Biochemistry (Mosc)       Date:  2013-11       Impact factor: 2.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.